Suvi Sorsa

Suvi Sorsa has extensive experience in cancer biology and gene therapy, especially with oncolytic viruses. She has co-authored dozens of scientific papers with an emphasis on tumor immunotherapy. She completed her PhD thesis at the Cancer Gene Therapy Group, University of Helsinki and has previous biotechnology experience from Ark Therapeutics, Kuopio, Finland. In 2015, Suvi joined TILT Biotherapeutics as Head of Research and Development and is currently responsible for TILT´s clinical research and clinical sample analysis. She has been involved in the development of the TILT´s viruses at every level – from initial studies in mouse models, through regulatory review, and now translating the preclinical research into clinical development.